HEK293 expression platform (L-10894/11266/11565) . : NR16-179/2017E-PDF
“There is an increasing demand for biopharmaceuticals such as vaccines, humanized monoclonal antibodies, and gene therapy products produced from animal cell culture processes. The NRC’s HEK293 expression system enables the high yield production of viral vector and post-translationally modified recombinant proteins through suspension-growing, serum-free adapted cell lines. It provides an optimized, chemically defined formulation for serum-free suspension culture of this cell line. The cell line can be used in combination with the cumate and coumermycin switches, which enable producers to turn on the expression of a given protein only when needed”--Highlights.
Lien permanent pour cette publication :
publications.gc.ca/pub?id=9.847672&sl=1
| Ministère/Organisme | National Research Council Canada. |
|---|---|
| Titre | HEK293 expression platform (L-10894/11266/11565) . |
| Type de publication | Monographie |
| Langue | [Anglais] |
| Autres langues publiées | [Français] |
| Format | Électronique |
| Document électronique | |
| Note(s) | Issued also in French under title: Plateforme d’expression HEK293 (L-10894/11266/11565). Caption title. "December 2017." Issued also in print format. |
| Information sur la publication | [Ottawa] : National Research Council Canada, [2018] |
| Description | [1] p. |
| ISBN | 9780660239897 |
| Numéro de catalogue |
|
| Descripteurs | Recombinant proteins Cultures and culture media HEK293 Cells |